Table 3. Number of subjects who reported injection site reactions*.
| Pain | Tenderness | Erythema | Swelling | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IM | ID | IM | ID | IM | ID | IM | ID | ||||
| (n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | ||||
| Grade 1 | 1 | 4 | 3 | - | - | 7 | - | 1 | |||
| Grade 2 | - | 2 | 4 | - | - | 1 | - | - | |||
| Grade 3 | - | - | - | - | - | - | - | - | |||
| Grade 4 | - | - | - | - | - | - | - | - | |||
In accordance with FDA toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.